Our Investors
The oligo therapeutic delivery market represents $25B in market value, but current modalities have many disadvantages including tissue penetration, route of administration, pharmacology, immunogenicity, and Chemistry, Manufacturing, and Controls (CMC). Creyon’s novel aptamer-delivered oligonucleotides enable cell specific delivery while avoiding antibody limitations.
5 Reasons to Believe in Aptamer Delivered Oligos
Targeted, aptamer-oligo conjugate crosses the blood brain barrier into the central nervous system (CNS).
In vivo proof-of-concept for transferrin receptor (TfR) aptamer delivers small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) across the BBB to knock down targets in CNS.
In vivo POC for TfR aptamer delivers ASOs into muscle supporting late-onset pompe disease program.
Aptamer-based lipid nanoparticles (LNP) targets T cells from in vitro to in vivo proof-of-concept.
Major multi-target platform partnership with Lilly.
Lilly Collaboration: $1B+ multi-target partnership to develop novel nucleic acid therapies.
